Drugs targeting poly (ADP-ribose) polymerase (PARP) to regulate cell proliferation and metastasis have gradually been applied in the clinical treatment of PCa (Risdon et al., 2021). The gene discussed is PARP1; the disease is posterior cortical atrophy.